Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.

For patients whose tumors are not methylated, the difference in OS favoring the TMZ and radiotherapy group was only marginally significant, with a median OS of 12.7 months among those GBM patients assigned to TMZ and radiotherapy, versus 11.8 months among those assigned to radiotherapy alone. 20 However, given the additional toxicities associated with TMZ, a discussion of risks versus benefits even in MGMT promoter methylated patients must also be considered and informed patient decisions made.

also in 5,076 other papers